SEC Comment Letter for Entero Therapeutics, Inc. (GRDX) (CIK 0001604191) (GRDX) — Nov 4, 2019
Entero Therapeutics, Inc. (GRDX) (CIK 0001604191)
Date: Nov. 4, 2019 · CIK: 0001604191 · Accession: 0000000000-19-015097
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-37853
Letter
November 4, 2019 James Sapirstein Chief Executive Officer AzurRx BioPharma, Inc. 760 Parkside Avenue Downstate Biotechnology Incubator, Suite 304 Brooklyn, NY 11226 Re:AzurRx BioPharma, Inc. Preliminary Proxy Statement on Schedule 14A Filed October 28, 2019 File No. 001-37853 Dear Mr. Sapirstein : We have reviewed your filing and have the following comment. Please respond to this comment within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to this comment, we may have additional comments. Preliminary Proxy Statement on Schedule 14A Proposal No. 2, page 18 1.Please revise your disclosure to discuss the potential dilutive effect of the reverse stock split and whether you have any current plans to issue the additional authorized shares that will result from the reverse stock split. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Ada D. Sarmento at 202-551-3798 or Celeste Murphy at 202-551-3257 with any questions.
FirstName LastNameJames Sapirstein Comapany NameAzurRx BioPharma, Inc. November 4, 2019 Page 2 FirstName LastName James Sapirstein AzurRx BioPharma, Inc. November 4, 2019 Page 2 Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jessica R. Sudweeks, Esq.
Show Raw Text
November 4, 2019
James Sapirstein
Chief Executive Officer
AzurRx BioPharma, Inc.
760 Parkside Avenue
Downstate Biotechnology Incubator, Suite 304
Brooklyn, NY 11226
Re:AzurRx BioPharma, Inc.
Preliminary Proxy Statement on Schedule 14A
Filed October 28, 2019
File No. 001-37853
Dear Mr. Sapirstein :
We have reviewed your filing and have the following comment.
Please respond to this comment within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe our
comment applies to your facts and circumstances, please tell us why in your response.
After reviewing your response to this comment, we may have additional comments.
Preliminary Proxy Statement on Schedule 14A
Proposal No. 2, page 18
1.Please revise your disclosure to discuss the potential dilutive effect of the reverse stock
split and whether you have any current plans to issue the additional authorized shares that
will result from the reverse stock split.
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
Please contact Ada D. Sarmento at 202-551-3798 or Celeste Murphy at 202-551-3257
with any questions.
FirstName LastNameJames Sapirstein
Comapany NameAzurRx BioPharma, Inc.
November 4, 2019 Page 2
FirstName LastName
James Sapirstein
AzurRx BioPharma, Inc.
November 4, 2019
Page 2
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jessica R. Sudweeks, Esq.